Literature DB >> 34168250

High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.

Ana M B Menezes1, Cesar G Victora2, Fernando P Hartwig2, Mariângela F Silveira2, Bernardo L Horta2, Aluísio J D Barros2, Marilia A Mesenburg2, Fernando C Wehrmeister2, Lúcia C Pellanda3, Odir A Dellagostin2, Cláudio J Struchiner4, Marcelo N Burattini5, Fernando C Barros2, Pedro C Hallal2.   

Abstract

Since the beginning of the pandemic of COVID-19, there has been a widespread assumption that most infected persons are asymptomatic. Using data from the recent wave of the EPICOVID19 study, a nationwide household-based survey including 133 cities from all states of Brazil, we estimated the proportion of people with and without antibodies for SARS-CoV-2 who were asymptomatic, which symptoms were most frequently reported, number of symptoms and the association with socio-demographic characteristics. We tested 33,205 subjects using a rapid antibody test previously validated. Information was collected before participants received the test result. Out of 849 (2.7%) participants positive for SARS-CoV-2 antibodies, only 12.1% (95% CI 10.1-14.5) reported no symptoms, compared to 42.2% (95% CI 41.7-42.8) among those negative. The largest difference between the two groups was observed for changes in smell/taste (56.5% versus 9.1%, a 6.2-fold difference). Changes in smell/taste, fever and body aches were most likely to predict positive tests as suggested by recursive partitioning tree analysis. Among individuals without any of these three symptoms, only 0.8% tested positive, compared to 18.3% of those with both fever and changes in smell or taste. Most subjects with antibodies against SARS-CoV-2 are symptomatic, even though most present only mild symptoms.

Entities:  

Year:  2021        PMID: 34168250     DOI: 10.1038/s41598-021-92775-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  1 in total

Review 1.  Taste and smell as chemosensory dysfunctions in COVID-19 infection.

Authors:  Pier Carmine Passarelli; Michele Antonio Lopez; Giuseppe Niccolò Mastandrea Bonaviri; Franklin Garcia-Godoy; Antonio D'Addona
Journal:  Am J Dent       Date:  2020-06       Impact factor: 1.522

  1 in total
  4 in total

1.  Self-reported symptoms and seroprevalence against SARS-CoV-2 in the population of Mato Grosso: a household-based survey in 2020.

Authors:  Ana Cláudia Pereira Terças-Trettel; Ana Paula Muraro; Amanda Cristina de Souza Andrade; Elaine Cristina de Oliveira
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-07       Impact factor: 1.712

2.  Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey.

Authors:  Lara E Coelho; Paula M Luz; Débora C Pires; Emilia M Jalil; Hugo Perazzo; Thiago S Torres; Sandra W Cardoso; Eduardo M Peixoto; Sandro Nazer; Eduardo Massad; Mariângela F Silveira; Fernando C Barros; Ana T R Vasconcelos; Carlos A M Costa; Rodrigo T Amancio; Daniel A M Villela; Tiago Pereira; Guilherme T Goedert; Cleber V B D Santos; Nadia C P Rodrigues; Beatriz Grinsztejn; Valdilea G Veloso; Claudio J Struchiner
Journal:  Lancet Reg Health Am       Date:  2022-07-30

3.  Prediction of SARS-CoV-2 infection with a Symptoms-Based model to aid public health decision making in Latin America and other low and middle income settings.

Authors:  Andrea Ramírez Varela; Sergio Moreno López; Sandra Contreras-Arrieta; Guillermo Tamayo-Cabeza; Silvia Restrepo-Restrepo; Ignacio Sarmiento-Barbieri; Yuldor Caballero-Díaz; Luis Jorge Hernandez-Florez; John Mario González; Leonardo Salas-Zapata; Rachid Laajaj; Giancarlo Buitrago-Gutierrez; Fernando de la Hoz-Restrepo; Martha Vives Florez; Elkin Osorio; Diana Sofía Ríos-Oliveros; Eduardo Behrentz
Journal:  Prev Med Rep       Date:  2022-04-20

4.  Antibody response three months after SARS-CoV-2 infection.

Authors:  Efdal Oktay Gültekin; Onur Gültekin; Arzu Coskun; Tiince Aksak
Journal:  J Med Virol       Date:  2022-06-10       Impact factor: 20.693

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.